Avid Bioservices Inc (CDMO)

[Protector]

Bavituximab a disruptive molecule or what?

What companies and which of there drugs will suffer from Bavituximab?

The players on one slide.

1) PS/PSR "Immune Upstream Checkpoint
Since Bavituximab is the only in its class anti-PS-Ligand we can skip that discussion. The other anti-PS-Receptor approaches are also UPSTREAM but do NOT have Bavituximab's equivalent in binding to the FC-Gamma receptor of M2 Macrophages, MDSC and immature dendric cells and hence DO NOT have the immune stimulatory effects bavituximab has. In Bavituximab The Movie one can immediately see why this is so important, a topic discussed between Analyst Rahul and CEO King on one of the Quarterly/CC's.

Axl (Genentech), TIM-1 (Celldex), TIM-4(Hokaido University) and TIM-3 (Novartis) are all in the PS-Receptor camp. Bavituximab not only makes the obsolete, but as expressed in a previous post Bavituximab is GENERIC by binding the PS-Ligand and does NOT affect the cell that holds the PS-receptor.

2) Immunosupressive Cytokines/Enzymes
TGF-Beta (Acceleron, ISA-RNA, Sanofi), and IL-10 (BMY, Takeda) are fire brigade approaches. When PS binds to M2 Macrophages and MDSCs the they secrete the immunosupressive substances TGF-bate and IL-10 that suppress the immune system. If you bind the anti-TGF-beta or anti-IL-10 to it then these molecules are no longer recognized as suppressors. However, bavituximab has a more performant approch, by eeping the PS-Ligand from binding with M2 Macophages and MDCSs there is no TGF-beta or IL-10 secretion to begin with. And again, this approach lacks all other tthings that Bavi does such as immune stimulation. So that renders them also obsolete.

IL-21 (BMY) and IDO (NewLink Genetics) are not part of the Bavituximab MOA and hence could have some added value.

3) Downstream Immune Checkpoint
We have already at the generic level emphasized many times that all down stream solutions work on one cell and do not activate the immune system at the generic level. Furthermore in this category the importance between Ligand or Receptor binding is very important.

In general Bavituximab poses no treat for PD-1 (BMY, Merck and AstraZeneca - Roche has one too), PD-L1 (AstraZeneca, Roche-Genentech, Merck) or CTLA-4 (BMY, AstraZeneca) as such. It combines with it and actually increases their responders footprint. At the same time it add all other Bavituximab advantages to the cocktail such as adaptive immune response triggering.

In this category the disruptive character of Bavituximab is the potential SOC and leader war disruptions. Each of them combined with Bavituximab wil; make SOC. And since Bavituximab is 100% controlled by PPHM (IP, pipelines and Prodcution - Bavituximab molecule is not in the public domain) it wheels some strategic power to PPHM. If one combination such as AstraZeneca's Durvalumab (anti-PD-L1)+Bavituximab makes it SOC it becomes VERY difficult to beat that with sufficient difference to take the SOC back using another PD-l1+Bavituximab. So AstraZeneca has an advantage here.

That leaves TIM-3 (which I don't fully understand in its downstream capacity) the does stuff with CD4/8. It is from Novartis and since in the PS receptor TIM-3 is obsolete this Downstream Immune Checkpoint the TIM-3 can play is all what is left for them. So here also a potential combination with Bavituximab.

Conclusion
One can see that Bavituximab by binding to the PS Ligand makes Axl, TIM1,3, 4 in the PS-receptor play filed, TGF-Beta and IL-10 are all obsolete because Bavituximab alone does all what they do AT ONCE.

The remaining IL-21, IDO and the downstream agents all combine with Bavituximab but have a competitive strategic risk because of it.

Furthermore bavituximab add anti-inflammatory and adaptive immune response as well as immune activation features to the mix that NON of the other approaches achieve.

I thing we are getting each day more and more prove that PS Ligand targeting is the way to go and that no cocktail WITHOUT Bavituximab has good changes to win battles in the coming years.